Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628678 | 1.00 | TRPM8 (0.57) | TRPM8NPC1RAB9AEPHX1RORC | |
| SCHEMBL15133483 | 1.00 | TRPM8 (0.57) | TRPM8NPC1RAB9AEPHX1RORC | |
| SCHEMBL14664188 | 1.00 | TRPM8 (0.57) | TRPM8NPC1RAB9AEPHX1RORC | |
| SCHEMBL5391878 | 0.88 | TRPM8 (0.55) | TRPM8EPHX1RORCCYP3A4 | |
| SCHEMBL15133431 | 0.88 | TRPM8 (0.55) | TRPM8EPHX1RORC | |
| SCHEMBL2628685 | 0.88 | TRPM8 (0.55) | TRPM8NPC1RAB9AEPHX1MEN1 | |
| SCHEMBL2628741 | 0.88 | RAB9A (0.58) | TRPM8NPC1RAB9AEPHX1MEN1 | |
| SCHEMBL5384391 | 0.86 | TRPM8 (0.53) | TRPM8EPHX1RORCCYP3A4 | |
| SCHEMBL10073868 | 0.86 | TRPM8 (0.73) | TRPM8NPC1RAB9AEPHX1MEN1 | |
| SCHEMBL15133487 | 0.86 | GLA (0.57) | TRPM8NPC1RAB9AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417048-B2 | Aryl-substituted derivatives of cycloalkyl and branched chain alkyl carboxylic acids useful as antinociceptive drugs for peripheral targets | WEI EDWARD T | 2008-08-26 | — | — | US | disclosed |
| US-20070053834-A1 | Radioligands for the TRP-M8 receptor and methods therewith | WEI EDWARD T | 2007-03-08 | — | — | US | disclosed |
| US-20070053834-A1 | Radioligands for the TRP-M8 receptor and methods therewith | WEI EDWARD T | 2007-03-08 | — | — | US | disclosed |
| US-7169377-B2 | Radioligands for the TRP-M8 receptor and methods therewith | WEI EDWARD T | 2007-01-30 | — | — | US | disclosed |
| US-20050187211-A1 | N-arylsalkyl-carboxamide compositions and methods | WEI EDWARD T (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050159394-A1 | Aryl-substituted derivatives of cycloalkyl and branched chain alkyl carboxylic acids useful as antinociceptive drugs for peripheral targets | WEI EDWARD T (US) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187211-A1 | N-arylsalkyl-carboxamide compositions and methods | OPRL1, TRPV1, TRPA1 | TRPM8 13/4885NPC1 1906/4885RAB9A 2610/4885 |
| US-20070053834-A1 | Radioligands for the TRP-M8 receptor and methods therewith | GPR68, TRPM8, OPRL1 | TRPM8 2/4885NPC1 1475/4885RAB9A 2137/4885 |
| US-20050159394-A1 | Aryl-substituted derivatives of cycloalkyl and branched chain alkyl carboxylic acids useful as antinociceptive drugs for peripheral targets | OPRL1, OPRK1, OPRD1 | TRPM8 588/4885NPC1 4105/4885RAB9A 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.